AMSTERDAM, May 2, 2011 /PRNewswire/ -- Leading events organiser UBM Live today announced details of the 2011 edition of ICSE China, which is dedicated to pharmaceutical contract services and outsourcing. ICSE, hosted from June 21-23, 2011 at the SNIEC China, is part of the most international pharmaceutical events line-up in China, which includes CPhI China for pharmaceutical ingredients, P-MEC China for pharma machinery and equipment, BioPh China for the biopharmaceuticals market and the new LABWorld pavilion for laboratory, analytical and biotechnology instrumentation technologies. Over 2,000 exhibitors and 27,000 visitors are expected over the three days. Attendance to the events is free through pre-registration at www.cphi-china.com.
"China's domestic market is expected to overtake Japan and become the world's second drug market by 2015(1)," noted Haf Cennydd, Brand Director, ICSE, P-MEC China and BioPh China. She further noted, "This continued growth has translated into continuously improving results for our events and has enabled us to constantly evolve our brands to reflect market trends. For this year's events we are excited to introduce a conference programme which will add even greater value for our visitors."
The inaugural China conference series, titled "Pharma R&D and Collaboration Strategies", will address global pharmaceutical issues, with an emphasis on China's pharma market, across key areas such as New Drug Discovery, Biopharm, Biosimilars, CRO/CMO, API Sourcing, Generics and Export Strategies and more. It will bring together Chinese and global pharma companies to explore different views regarding the China pharmaceutical market. Thirty eminent speakers from international pharmaceutical companies and research institutes, such as the FDA, Novartis, USP-China, Roche R&D Center, GSK China/HK, AstraZeneca Innovation Centre China, sanofi-aventis, REVA PHARMA, Dr. Reddy's and Shanghai Pharma, will share their knowledge and research strategies. Additionally, in-depth case studies covering R&D and business development strategies will be presented by an outstanding panel of Chinese, Indian and international speakers from industry leading companies and associations.
The introduction of the conference programme to the China events follows the successful launch of a similar series at the CPhI Worldwide, CPhI South America and CPhI India events and is expected to draw over 400 attendees. The series will be offered in seven individually bookable 3-hour modules and further information can be found at: www.cphichina-conference.com.
ICSE China offers a meeting place for major Chinese contract research organizations (CRO) and contract manufacturing organizations (CMO). By partnering with the co-located events, ICSE looks to offer comprehensive industry access within the growing Chinese pharma market. Currently, contract services and outsourcing are booming sectors in the Chinese pharma market. Suppliers within this market have been able to successfully identify new areas for expansion in both the domestic and global markets and ICSE and co-located events provide face-to-face access to this growing market. The synergy between the events further serves to improve the visitor experience during the time spent in Shanghai.
The annual schedule of global ICSE events also includes ICSE Japan (13-15, July, 2011, Intex Osaka Exhibition Centre, Osaka, Japan), ICSE South America (24-26, August, 2011, Transamerica Expo Center, Sao Paola, Brazil), ICSE (25-27, October, Messe Frankfurt, Germany), and ICSE India (30 November – 2 December, 2011, Bombay Exhibition Centre, Mumbai, India). Further information about ICSE and its co-located events can be found online at www.icsexpo.com, www.cphi.com, www.p-mec.com and www.bioph-online.com.
(1) ARC China December 4, 2010 Newsletter
Notes for Editors:
|SOURCE UBM Live|
Copyright©2010 PR Newswire.
All rights reserved